Overview
LXEO market data
Price History
LXEO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.60 – $10.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $369.4 · P/B 2.94 · P/S 535.16.
Company news
Fermi, Delta Air Lines And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jul 10, 2026, 12:05 PM
JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9Benzinga · Jun 25, 2026, 3:00 PM
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA CardiologyBenzinga · Jun 17, 2026, 8:10 PM
Why Is Lexeo Therapeutics Stock Gaining Monday?Benzinga · Jun 15, 2026, 3:35 PM
Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intended To Provide Clinical Evidence To Support Submission FDA Application For Gene Therapy Candidate LX2006 Under The Accelerated Approval Pathway In 2028Benzinga · Jun 15, 2026, 11:10 AM
8-K filing — Lexeo Therapeutics, Inc. (LXEO)SEC EDGAR · Jun 15, 2026, 11:05 AM
Lexeo Therapeutics Q1 EPS $(0.25) Beats $(0.33) Estimate, Cash, Cash Equivalents And Investments Of $227.6M Expected To Provide Operational Runway Into 2028Benzinga · May 11, 2026, 11:21 AM